Cello Group plc (CLL) Scheduled to Post Quarterly Earnings on Wednesday
Cello Group plc (LON:CLL) is scheduled to issue its quarterly earnings data before the market opens on Wednesday, September 14th.
Separately, Peel Hunt restated a “buy” rating and set a GBX 130 ($1.73) price target on shares of Cello Group plc in a report on Tuesday, July 26th.
Cello Group plc (LON:CLL) opened at 109.00 on Tuesday. The company’s market cap is GBX 92.98 million. The stock has a 50 day moving average price of GBX 102.80 and a 200-day moving average price of GBX 96.79. Cello Group plc has a 12-month low of GBX 77.10 and a 12-month high of GBX 115.00.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/13/cello-group-plc-cll-scheduled-to-post-quarterly-earnings-on-wednesday.html
In other Cello Group plc news, insider Scott,Mark purchased 101,525 shares of Cello Group plc stock in a transaction that occurred on Monday, June 20th. The shares were bought at an average price of GBX 97 ($1.29) per share, for a total transaction of £98,479.25 ($131,165.76).
Cello Group plc Company Profile
Cello Group plc is a United Kingdom-based healthcare and consumer strategic marketing company. The Company is engaged in providing market research, consulting and direct marketing services. The Company operates through two segments: Cello Health and Cello Signal. The Cello Health Division provides market research, consulting and communications services principally to the Company’s pharmaceutical and healthcare clients.
Receive News & Ratings for Cello Group plc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cello Group plc and related companies with MarketBeat.com’s FREE daily email newsletter.